Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-12-18

FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)

View source ↗

Summary

The FDA approved a supplemental application for rivastigmine submitted by Sandoz Inc. This action updates rivastigmine's regulatory status through a supplementa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rivastigmine (Rivastigmine)

Snippet

SUPPL AP for RIVASTIGMINE (RIVASTIGMINE)